Effect of the neridronate on RANKL release in differentiated primary human osteoblasts

Bisphosphonates are important inhibitors of bone resorption and widely used clinically to treat osteoporosis, metabolic bone diseases and other orthopaedic disorders . Inhibiting osteoclasts via the mevalonate pathway is rec- ognized as the primary mechanism of its inhibitory action. Recent evidence suggests that bisphosphonates may regulate essential signaling molecules involved in osteoclastoge- nesis such as RANKL (receptor activator of NF- kB ligand) which are synthesized by osteoblasts. In this report we have investigated into the neridronate-osteoblast interactions in modulating essential signaling molecule such as RANKL.